1-6 of 6
Judith M. Bliss
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter, Kathryn Dunne, Ellen Copson, Tamas Hickish, Russell Burcombe, Kat Randle, Violeta Serra, Alba Llop-Guevara, Judith M. Bliss, Nicolas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4751–4759.
https://doi.org/10.1158/1078-0432.CCR-23-1696
Published: 01 December 2023
View article titled, Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Open the PDF for Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) in another window
Includes: Supplementary data
Journal Articles

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, Abeer M. Shaaban, Emad A. Rakha, Anne Armstrong, Ramsey I. Cutress, David Dodwell, Marie A. Emson, Abigail Evans, Sue M. Hartup, Kieran Horgan, Sarah E. Miller, Stuart A. McIntosh, James P. Morden, Jay Naik, Sankaran Narayanan, Jane Ooi, Anthony I. Skene, David A. Cameron, Judith M. Bliss
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1323–1334.
https://doi.org/10.1158/1078-0432.CCR-21-3177
Published: 01 April 2022
View article titled, Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Open the PDF for Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results in another window
Includes: Supplementary data
Journal Articles

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

Milana A. Bergamino, Gabriele Morani, Joel Parker, Eugene F. Schuster, Mariana F. Leal, Elena López-Knowles, Holly Tovey, Judith M. Bliss, John F.R. Robertson, Ian E. Smith, Mitch Dowsett, Maggie C.U. Cheang
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1217–1228.
https://doi.org/10.1158/1078-0432.CCR-21-2718
Published: 15 March 2022
View article titled, Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Open the PDF for Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2− Breast Cancer

Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dodson, Vera Martins, Maggie Cheang, Sophie Perry, Chris Holcombe, Nick Turner, Claire Swift, Judith M. Bliss, Stephen Johnston, on behalf of the PALLET trialists
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 163–174.
https://doi.org/10.1158/1078-0432.CCR-21-1628
Published: 01 January 2022
View article titled, Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Open the PDF for Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>−</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen R.D. Johnston, Stephen K. Chia
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (19): 5172–5177.
https://doi.org/10.1158/1078-0432.CCR-20-0224
Published: 01 October 2020
View article titled, <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Open the PDF for <em>ESR1</em> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials in another window
Includes: Supplementary data
Journal Articles

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

Alexandra Leary, Abigail Evans, Stephen R.D. Johnston, Roger A'Hern, Judith M. Bliss, Rashmita Sahoo, Simone Detre, Benjamin P. Haynes, Margaret Hills, Catherine Harper-Wynne, Nigel Bundred, Gill Coombes, Ian Smith, Mitch Dowsett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2932–2940.
https://doi.org/10.1158/1078-0432.CCR-14-1428
Published: 30 June 2015
View article titled, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Open the PDF for Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) in another window
Includes: Supplementary data